HK1212995A1 - 種純化蛋白質的方法 - Google Patents

種純化蛋白質的方法

Info

Publication number
HK1212995A1
HK1212995A1 HK16100830.6A HK16100830A HK1212995A1 HK 1212995 A1 HK1212995 A1 HK 1212995A1 HK 16100830 A HK16100830 A HK 16100830A HK 1212995 A1 HK1212995 A1 HK 1212995A1
Authority
HK
Hong Kong
Prior art keywords
purifying proteins
purifying
proteins
Prior art date
Application number
HK16100830.6A
Other languages
English (en)
Chinese (zh)
Inventor
Nathan Brinkman
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/803,525 external-priority patent/US9534029B2/en
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of HK1212995A1 publication Critical patent/HK1212995A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16100830.6A 2012-10-03 2016-01-26 種純化蛋白質的方法 HK1212995A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261709342P 2012-10-03 2012-10-03
US13/803,525 US9534029B2 (en) 2012-10-03 2013-03-14 Method of purifying proteins
AU2013203930A AU2013203930B2 (en) 2012-10-03 2013-04-11 A method of purifying proteins
EP13170202 2013-06-03
PCT/US2013/062916 WO2014055552A1 (fr) 2012-10-03 2013-10-01 Méthode de purification des protéines

Publications (1)

Publication Number Publication Date
HK1212995A1 true HK1212995A1 (zh) 2016-06-24

Family

ID=52824845

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100830.6A HK1212995A1 (zh) 2012-10-03 2016-01-26 種純化蛋白質的方法

Country Status (8)

Country Link
EP (1) EP2904005A1 (fr)
JP (2) JP6370792B2 (fr)
KR (2) KR102125695B1 (fr)
CN (2) CN112717125A (fr)
CA (2) CA2886726C (fr)
HK (1) HK1212995A1 (fr)
SG (1) SG11201501921SA (fr)
WO (1) WO2014055552A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887588T3 (es) * 2015-08-13 2021-12-23 Kamada Ltd Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas
JPWO2017170597A1 (ja) * 2016-03-29 2019-02-14 協和発酵キリン株式会社 血中でハプトグロビンに結合して多価の免疫複合体を形成する抗体を有効成分とする自己免疫疾患治療剤
SG11202000210UA (en) * 2017-08-08 2020-02-27 Csl Behring Ag Hemopexin formulations
JP6600123B1 (ja) * 2018-04-18 2019-10-30 積水メディカル株式会社 ヘモグロビン分析方法
CA3138650A1 (fr) 2019-05-17 2020-11-26 Universitaet Zuerich Haptoglobine destinee a etre utilisee dans le traitement d'un evenement neurologique secondaire indesirable suite a un avc hemorragique
CN117136068A (zh) 2021-02-01 2023-11-28 瑞士杰特贝林生物制品有限公司 治疗或预防出血性中风后不良继发性神经学后果的方法
US20240034749A1 (en) * 2021-02-04 2024-02-01 Green Cross Corporation Method for purification of hemopexin and haptoglobin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5337406B2 (fr) * 1973-11-15 1978-10-09
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6317899A (ja) * 1986-07-09 1988-01-25 Green Cross Corp:The ハプトグロビンの精製方法
JPH01305036A (ja) * 1988-05-31 1989-12-08 Green Cross Corp:The 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
SE9301582D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
DE19830914C1 (de) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Verfahren zur Herstellung einer Proteinlösung
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
DE10215315A1 (de) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels
AU2002307776A1 (en) * 2002-04-16 2003-10-27 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
JP2004224793A (ja) * 2003-01-17 2004-08-12 Research Corp Technologies Inc 子宮内膜症の治療方法
JP2004256463A (ja) * 2003-02-26 2004-09-16 Univ Waseda 多形核白血球の細胞接着抑制剤及び細胞接着抑制方法
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP2009537812A (ja) * 2006-05-15 2009-10-29 デジラブ インコーポレーテッド ２型糖尿病プリフォームのバイオマーカー、及び２型糖尿病プリフォームの存在又は不在を検出する方法
CN101778860B (zh) * 2007-08-17 2013-07-10 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
EP2027875A1 (fr) * 2007-08-23 2009-02-25 Octapharma AG Processus d'isolation et de purification d'une protéine cible libre de protéine de prion (PrPSC)
KR101426039B1 (ko) * 2008-09-11 2014-08-01 삼성테크윈 주식회사 얼굴/물체 인식을 위한 특징점 검출 장치 및 방법
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
EP2236617A1 (fr) * 2009-03-31 2010-10-06 Leukocare Ag Procédés de stérilisation de terminal de compositions biofonctionnelles
WO2011002070A1 (fr) * 2009-07-02 2011-01-06 協和発酵キリン株式会社 Composition pharmaceutique pour le traitement de troubles ou maladies de surcharge en fer, grâce à laquelle la réduction de concentration en fer est efficace, et qui comprend la protéine gdf7/bmp12
WO2011007208A1 (fr) * 2009-07-16 2011-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composés et procédés pour le traitement du cancer
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
CN102471368A (zh) * 2009-08-11 2012-05-23 拜康有限公司 色谱方法及其纯化的化合物
DK2947148T3 (en) * 2010-04-20 2017-09-18 Octapharma Ag NEW STABILIZER FOR PHARMACEUTICAL PROTEINS
WO2012050874A2 (fr) * 2010-09-28 2012-04-19 Soares Miguel P Ciblage de l'hème pour le traitement de maladies inflammatoires à médiation immunitaire

Also Published As

Publication number Publication date
KR20150063547A (ko) 2015-06-09
JP6370792B2 (ja) 2018-08-08
CA2886726A1 (fr) 2014-04-10
JP6876655B2 (ja) 2021-05-26
CA2886726C (fr) 2021-11-23
KR102125695B1 (ko) 2020-06-24
CA3129057A1 (fr) 2014-04-10
KR102231613B1 (ko) 2021-03-25
EP2904005A1 (fr) 2015-08-12
CN112717125A (zh) 2021-04-30
JP2018172426A (ja) 2018-11-08
CA3129057C (fr) 2023-03-07
SG11201501921SA (en) 2015-04-29
CN104968676A (zh) 2015-10-07
KR20200075027A (ko) 2020-06-25
WO2014055552A1 (fr) 2014-04-10
JP2015532301A (ja) 2015-11-09

Similar Documents

Publication Publication Date Title
HRP20181357T1 (hr) Novi postupci pročišćavanja proteina
HK1214833A1 (zh) 種純化治療性蛋白質的方法
EP2883882A4 (fr) Procédé de purification des protéines
GB201217772D0 (en) Sequencing method
IL232558B (en) A method for antibody purification
PT2768857T (pt) Métodos para purificar anticorpos
ZA201305971B (en) Method for the purification of biphephos
HRP20190030T1 (hr) Postupak pročišćavanja protutijela
EP2727930A4 (fr) Procédé de purification d'une protéine
HK1212995A1 (zh) 種純化蛋白質的方法
SG11201405296QA (en) Method for purifying acetonitrile
GB201222693D0 (en) Novel method
SG10201606218WA (en) Purified Proteins
EP2697245A4 (fr) Procédés de purification de l'hydrophobine
GB201220155D0 (en) Method of manufacture
SG11201501216XA (en) Method for purifying acetonitrile
SI3202769T1 (sl) Postopek čiščenja za fosfaplatinove spojine
GB201209082D0 (en) Purification method
EP2743258A4 (fr) Procédé pour purifier le lévo-oxiracétam
EP2737065A4 (fr) Procédé de production de protéines
SG2013017017A (en) A method of separation
EP2762486A4 (fr) Procédé de purification de protéine
GB201105407D0 (en) Purification method
SG10201703786YA (en) Nox removal method
GB201215942D0 (en) Method of treatent